BREAST CANCER The 21-gene recurrence score - biology remains at the forefront

Puhalla Shannon L.; Davidson Nancy E.

首页> 外文期刊>Nature reviews. Clinical oncology >BREAST CANCER The 21-gene recurrence score - biology remains at the forefront

【24h】

BREAST CANCER The 21-gene recurrence score - biology remains at the forefront

机译：乳腺癌21基因复发评分-生物学仍处于最前沿

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The 21-gene recurrence score is a genetic assay developed to estimate the likelihood of distant recurrence in patients with oestrogen-receptor-positive, lymph-node-negative breast cancer treated with adjuvant endocrine therapy. Now, two studies explore how the 21-gene recurrence score has been used to inform treatment decisions in this setting and beyond.

机译：21基因复发评分是一种遗传测定方法，旨在评估接受辅助内分泌治疗的雌激素受体阳性，淋巴结阴性乳腺癌患者远处复发的可能性。现在，两项研究探索了在这种情况下以及以后如何使用21基因复发评分来指导治疗决策。

著录项

来源
《Nature reviews. Clinical oncology 》 |2016年第8期| 共2页
作者
Puhalla Shannon L.; Davidson Nancy E.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. BREAST CANCER The 21-gene recurrence score - biology remains at the forefront [J] . Puhalla Shannon L., Davidson Nancy E. Nature reviews. Clinical oncology . 2016 ,第8期

机译：乳腺癌21基因复发评分-生物学仍处于最前沿
2. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population [J] . SgroiD.C., SestakI., CuzickJ., The lancet oncology . 2013 ,第11期

机译：雌激素受体阳性乳腺癌患者晚期远距离复发的预测：TransATAC研究人群中乳腺癌指数（BCI）测定，21基因复发评分和IHC4的前瞻性比较
3. Breast cancer-specific survival in 6,768 patients with lymph nodepositive (LN plus ) hormone receptor-positive (HR plus ) invasive breast cancer (BC) and 21-gene Recurrence Score (R) (RS) results in the SEER registries [J] . Shak S., Roberts M., Petkov V. I., The Breast : . 2017 ,第期

机译：6,768名淋巴结患者的乳腺癌癌细胞存活率（LN Plus）激素受体阳性（HR加）侵入性乳腺癌（BC）和21-基因复发评分（R）（RS）导致SEER注册表
4. Prediction of Oncotype DX recurrence score in breast cancer by integration of DCE-MRI radiomics and clinicopathologic data [C] . Yajing Cui, Ming Fan, Weijun Peng, Conference on Medical Imaging: Imaging Informatics for Healthcare, Research, and Applications . 2021

机译：DCE-MRI辐射瘤和临床病理数据集成乳腺癌在乳腺癌中的癌型DX复发评分的预测
5. Economic evaluation of 21-gene assay for early stage breast cancer patients from the perspective of the Chinese health care system. [D] . Zhou, Mi. 2012

机译：从中国卫生保健系统的角度对早期乳腺癌患者进行21基因检测的经济评价。
6. Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early-Stage Estrogen Receptor–Positive Breast Cancer [O] . Catherine M. Kelly, Philip S. Bernard, Savitri Krishnamurthy, 2012

机译：早期雌激素受体阳性乳腺癌的21基因复发评分测定法（OncotypeDX®）与PAM50乳腺癌固有分类器™之间的风险预测协议
7. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores [O] . Takeo Fujii, Hiroko Masuda, Yee Chung Cheng, 2021

机译：A 95基因签名分层侵袭性疾病的复发风险，具有中间体21-基因签名复发评分

BREAST CANCER The 21-gene recurrence score - biology remains at the forefront

摘要

著录项

相似文献

相关主题

期刊订阅